A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
for Non-Small Cell Lung Cancer
Drug: Divarasib
Sites in Mineola, The Bronx +9 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT05789082·Phase 1, Phase 2·Recruiting·Listed Mar 2023